{"filing":{"accession_number":"0001213900-26-099702","cik":"0001946563","ticker":"SXTPW","company_name":"60 DEGREES PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-12","primary_document":"ea0305442-8k_60degree.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026099702/ea0305442-8k_60degree.htm"},"events":[{"id":33261,"run_id":30582,"accession_number":"0001213900-26-099702","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"60 Degrees Pharmaceuticals disclosed submission of a Statement of Interest to the FDA requesting a Commissioner's National Priority Voucher (CNPV) for an efficacy supplement to support potential FDA approval of tafenoquine for babesiosis treatment. This is a material regulatory and strategic milestone—the CNPV could accelerate approval timelines and enable the first FDA-approved babesiosis therapy. While the filing emphasizes clinical efficacy signals and regulatory pathway, the core disclosed event is a strategic regulatory filing that would materially affect the company's development timeline and commercial prospects, fitting operational_other as a material business development event not captured by more specific categories.","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":36657,"accession_number":"0001213900-26-099702","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"60 Degrees Pharmaceuticals disclosed submission of a Statement of Interest to the FDA requesting a Commissioner's National Priority Voucher (CNPV) for an efficacy supplement to support potential FDA approval of tafenoquine for babesiosis treatment. This is a material regulatory and strategic milestone—the CNPV could accelerate approval timelines and enable the first FDA-approved babesiosis therapy. While the filing emphasizes clinical efficacy signals and regulatory pathway, the core disclosed event is a strategic regulatory filing that would materially affect the company's development timeline and commercial prospects, fitting operational_other as a material business development event not captured by more specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:08:55.155037+00:00","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-09-14"}]}